BiomX Provides a Program Update and Announces New FDA Feedback Potentially Expanding BX004 Development Pathways

BiomX believes that it has fully addressed the FDA’s queries related to the third-party nebulizer used to deliver BX004, which are narrow in scope; an additional FDA request for limited technical clarifications on the nebulizer has also been addressed

Read more at globenewswire.com